Gliaid M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The combination of these two agents provides complementary mechanisms of action, resulting in more effective blood glucose regulation than either agent alone. Gliaid M2 Tablet PR is prescribed for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. It is important to initiate treatment with appropriate lifestyle modifications and to monitor blood glucose levels regularly to minimize the risk of hypoglycemia and other adverse effects. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, which are generally transient. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Gliaid M2 Tablet PR should be used under medical supervision, with dose adjustments based on clinical response and tolerability.